dijous 15 de novembre de 2018

Anti-inflammatory drugs could improve the cognitive disorders that occur when quitting smoking

News from the DCEXS-UPF

A team of scientists from the Neuropharmacology Laboratory-NeuroPhar of Pompeu Fabra University has shown in a study in rodents that treatment with anti-inflammatory drugs reverses the cognitive disorders caused by nicotine withdrawal. The work, led by the researchers Fernando Berrendero and Rafael Maldonado, has been published in the journal Brain, Behavior and Immunity.

Early nicotine withdrawal causes numerous undesirable effects, including physical, affective and cognitive symptoms which include attention deficits and memory impairment. Several studies suggest that these cognitive disordersare involved in relapse into tobacco consumption that occurs in the first few days after attempting to quit. In fact, varenicline, a drug marketed to treat tobacco addiction, works by enhancing mood and cognitive function at the beginning of the withdrawal period.


“The chance of being able to use anti-inflammatory drugs to address one of the lesser known aspects of nicotine withdrawal, learning and memory disorders -that play a key role in relapse to consumption- can open a highly innovative treatment strategy to treat nicotine dependency”, concludes Rafael Maldonado, full professor of Pharmacology at UPF.


More information:
DCEXS-UPF website

Saravia R, Ten-Blanco M, Grande MT, Maldonado R, Berrendero F. Anti-inflammatory agents for smoking cessation? Focus on cognitive déficits associated with nicotine withdrawal in male mice. Brain, Behavior, and Immunity, November 2018. https://doi.org/10.1016/j.bbi.2018.11.003